January - 2020

MECFA Blog

Raleigh biotech startup Arrevus gets FDA support for its drug treating cystic fibrosis patients

RALEIGH — Cystic fibrosis (CF) is a heredity disease with no cure. However, Raleigh biotech startup Arrevus believes it owns a drug that...

Organ Care System Used at Florida Hospital Expected to Make More Lungs Suitable for Transplant

Tampa General Hospital (TGH) announced that is the first in Florida to use an organ care system that allows donor lungs, hearts, and...

Creating Intestinal Organoids In Vitro

Scientists in Boston say they have developed a new method for generating groups of intestinal cells that can be used, among others, to...

CF Carriers at Increased Risk for Disease-related Conditions, Study Reports

Cystic fibrosis carriers — individuals who have certain genetic mutations in one of the copies of the CFTR gene — have a significantly...

SIMPLE TREATMENT OF TYPE 2 DIABETES WITH A LOW-CALORIE DIET IS SO EFFECTIVE THAT IT REVERSES THE DIS

A “revolutionary” treatment plan for type 2 diabetes has made the British National Health Service (NHS) very active as they position...

5 FDA approval decisions to watch in the 1st quarter

Credit: Yujin Kim / MedTech Dive, original photo courtesy of U.S. Food and Drug Administration The Food and Drug Administration cleared...

Medical Mystery: It took more than 50 years to find out why his health was so poor

For as long as he can remember, Steven Knapp never felt well. “That was pretty much true from early childhood,” said Knapp, a...

New agents to fight multidrug-resistant germs

Resistance to antibiotics is on the rise worldwide. Fraunhofer scientists have joined forces with partners in the Phage4Cure project to...

CF Newborn Screening Improves Weight and Lung Outcomes, but Has No Impact on Social Inequalities, St

Babies diagnosed with cystic fibrosis (CF) through newborn bloodspot screening show better lung function, can better stave off infection...

Disease Duration, Flare-ups Affect Mental Health of Non-CF Bronchiectasis Patients, Study Finds

VERTEX’S CF BLOCKBUSTER TRIKAFTA EFFECTIVE IN KIDS 6 TO 11 YEARS OF AGE

A case for improved carrier screening

Vertex to Seek Expanded FDA Approval for Trikafta After Positive Child Safety Data

Vertex’s Kaftrio approved for use in Europe and made accessible on the NHS

Age May Affect Outcomes in Lung Transplant Recipients With Cystic Fibrosis

CFF Funding Will Further ContraFect’s Research Into Alternative for Antibiotics

The search for molecular glue in targeted disease control

Vest Therapy Lowers Risk of Hospitalization in Non-CF Bronchiectasis, Study Says

Harvard is working with Boston hospitals to test existing cystic fibrosis drug to help coronavirus p